"We are pleased that our patent and intellectual property portfolio continues to grow in area of automated biological agent detection and identification," commented M. Allen Northrup Ph.D., Founder and CEO. "With these additional patents and our on-going program to build and test these automated systems, we are well on the way to implementing a key solution to airborne pathogen monitoring," he added.
Microfluidic Systems (MFSI), www.microfluidicsystems.com , was founded in 2001 and is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. MFSI personnel have been involved with the development of automated pathogen detection systems and microfluidics for the US Government and commercial markets for over 25 years. For more information, please contact Dr. Northrup at MFSI at 510-354-0400 ext 201, or visit the website, www.microfluidicsystems.com.
Statements in this press release are forward-looking. Actual results might differ from these statements due to unforeseen events and uncertainties. MFSI disclaims any intention to or obligation to update these forward-looking statements.
M. Allen Northrup Ph.D. | |
CEO and Chief Technology Officer | |
MicroFluidic Systems | |
47790 Westinghouse Dr | |
Fremont, CA 94539 | |
510-354-0400 ext 201 | |
510-354-0404 (fax) | |
SOURCE Microfluidic Systems